Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abrocitinib

FDA-approved product (tablet, oral), marketed as Cibinqo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abrocitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abrocitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abrocitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

    NCT07448363 · start 2026-05

    Registered record
    Registry ID
    NCT07448363
    Conditions
    Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema); Atopic Dermatitis Patients; Atopic Dermatitis / Eczema; Atopic Dermatitis, Unspecified
    Interventions
    Abrocitinib; Upadacitinib; Baricitinib; Dupilumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2031-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema); Atopic Dermatitis Patients +2 more
    InterventionAbrocitinib; Upadacitinib; Baricitinib; Dupilumab
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

    NCT06899204 · start 2026-04-24

    Registered record
    Registry ID
    NCT06899204
    Conditions
    Atopic Dermatitis; Atopic Dermatitis, Unspecified; Dermatitis, Atopic
    Interventions
    Abrocitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-04-24
    Completion
    2027-02-15
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Atopic Dermatitis, Unspecified; Dermatitis, Atopic
    InterventionAbrocitinib
    PhaseNot recorded
    Registry statusRecruiting

  • A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

    NCT06807281 · start 2025-12-02

    Registered record
    Registry ID
    NCT06807281
    Conditions
    Atopic Dermatitis
    Interventions
    Abrocitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-02
    Completion
    2032-02-22
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAbrocitinib
    PhasePhase 3
    Registry statusRecruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

    NCT06807268 · start 2025-07-24

    Registered record
    Registry ID
    NCT06807268
    Conditions
    Eczema
    Interventions
    Abrocitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-07-24
    Completion
    2027-05-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema
    InterventionAbrocitinib; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

    NCT06597396 · start 2024-12-27

    Registered record
    Registry ID
    NCT06597396
    Conditions
    Post-COVID Condition; Fatigue Symptom
    Interventions
    Abrocitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-12-27
    Completion
    2026-09-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-COVID Condition; Fatigue Symptom
    InterventionAbrocitinib; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

    NCT06573593 · start 2024-07-29

    Registered record
    Registry ID
    NCT06573593
    Conditions
    Alopecia Areata; Janus Kinase Inhibitors
    Interventions
    Tofacitinib; Baricitinib; Ruxolitinib; Upadacitinib; Abrocitinib; Ritlecitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-07-29
    Completion
    2026-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata; Janus Kinase Inhibitors
    InterventionTofacitinib; Baricitinib; Ruxolitinib; Upadacitinib +2 more
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

    NCT06283550 · start 2024-05-31

    Registered record
    Registry ID
    NCT06283550
    Conditions
    Chronic Hand Eczema
    Interventions
    Abrocitinib 200 mg; Abrocitinib 100 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-05-31
    Completion
    2025-11-03
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hand Eczema
    InterventionAbrocitinib 200 mg; Abrocitinib 100 mg; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Registry for Systemic Eczema Treatments

    NCT06136767 · start 2024-01-17

    Registered record
    Registry ID
    NCT06136767
    Conditions
    Atopic Dermatitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-17
    Completion
    2030-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Janus Kinase Inhibition in Granuloma Annulare

    NCT05650736 · start 2023-10-27

    Registered record
    Registry ID
    NCT05650736
    Conditions
    Granuloma Annulare
    Interventions
    Abrocitinib 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-10-27
    Completion
    2025-07-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranuloma Annulare
    InterventionAbrocitinib 200 mg
    PhasePhase 2
    Registry statusActive not recruiting

  • Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

    NCT06366932 · start 2023-09-25

    Registered record
    Registry ID
    NCT06366932
    Conditions
    Atopic Dermatitis
    Interventions
    Second-line systemic treatment; Folllow-up of second-line systemic treatment already started
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-09-25
    Completion
    2025-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionSecond-line systemic treatment; Folllow-up of second-line systemic treatment already started
    PhasePhase 4
    Registry statusUnknown

  • A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

    NCT05721937 · start 2023-07-25

    Registered record
    Registry ID
    NCT05721937
    Conditions
    Atopic Dermatitis
    Interventions
    Abrocitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-07-25
    Completion
    2027-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAbrocitinib
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

    NCT06119490 · start 2023-07-05

    Registered record
    Registry ID
    NCT06119490
    Conditions
    Toxic Epidermal Necrolysis
    Interventions
    Abrocitinib; Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-07-05
    Completion
    2026-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxic Epidermal Necrolysis
    InterventionAbrocitinib; Tofacitinib
    PhaseEarly phase 1
    Registry statusRecruiting

  • A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

    NCT05391061 · start 2023-01-07

    Registered record
    Registry ID
    NCT05391061
    Conditions
    Dermatitis, Atopic
    Interventions
    Abrocitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-01-07
    Completion
    2027-11-22
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionAbrocitinib
    PhaseNot recorded
    Registry statusRecruiting